Heidelberg Pharma GmbH is a company providing pre-clinical drug discovery and development services. Services include explorative pharmacology in the field of cancer, autoimmunity and inflammation, hand-in-hand with bioanalytical methods. Our performance for our clients is characterized by a high degree of flexibility, rapid turn-around and consistent high quality. Heidelberg Pharma's own R&D flagship is its proprietary 2nd generation ADC technology for more effective anti-cancer drugs.
News & Events: September 2013
Heidelberg Pharma, a wholly owned subsidiary of WILEX AG, signs license agreement for the development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche [...]